Calmare Therapeutics Appoints Christine Chansky, M.D., J.D., F.C.L.M., Chief Regulatory Officer

FAIRFIELD, Conn.--(BUSINESS WIRE)--Calmare Therapeutics Incorporated, (OTCQB:CTTC) (CTI), the Calmare® chronic pain and wound care company, has appointed Dr. Christine Chansky, M.D., J.D., F.C.L.M., chief regulatory officer (CRO) of Calmare Therapeutics.

Suggested Articles

Minerva's seltorexant helped patients fall asleep more quickly and stay asleep for longer, beating placebo and Sanofi’s Ambien in a phase 2b study.

Cannabidiol might work as a powerful antibiotic against certain drug-resistant bacteria such as methicillin-resistant S. aureus.

Krystal Biotech posted data from a phase 2 study showing its topical gene therapy closed the majority of wounds in patients with a rare skin disorder.